NIH-funded research R01 grant

Investigating Connexin 43's role in heart issues related to Duchenne muscular dystrophy

Official title: Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy

Funded at Rutgers Biomedical and Health Sciences · NIH-11132829 · Data updated 2026-11-12

This study is looking at how a protein called Connexin 43 affects heart health in people with Duchenne muscular dystrophy, with the goal of finding new ways to help prevent heart problems like arrhythmias and heart failure.

More Cardiomyopathy research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionRutgers Biomedical and Health Sciences
NIH-funded
Lab location1 site (Newark, UNITED STATES)
Project startJuly 15, 2024
Project endMay 31, 2028
Funding year2025
Award (this year)$688,593
NIH project number5R01HL171094-02
Project IDNIH-11132829 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy who are experiencing or at risk for heart complications.

Less likely to help

Patients without Duchenne muscular dystrophy or those who do not have heart-related issues associated with the condition may not benefit from this research.

What this research studies

This research focuses on understanding how a protein called Connexin 43 (Cx43) contributes to heart problems in patients with Duchenne muscular dystrophy (DMD). The study aims to explore how changes in Cx43 affect heart cell function and lead to arrhythmias and heart failure. By examining the relationship between Cx43 and the microtubule network in heart cells, researchers hope to identify new therapeutic targets that could improve heart health in DMD patients. The approach involves detailed analysis of heart cell behavior and the molecular mechanisms at play.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that improve heart function and reduce the risk of heart failure in patients with Duchenne muscular dystrophy.

How similar studies have gone: Previous research has shown promising results in targeting similar molecular pathways to improve heart function in other conditions, suggesting potential for success in this novel approach.

Where this research is happening

  • Rutgers Biomedical and Health Sciences
    Newark, United States
    Active

Researchers

  • Principal investigator: Fraidenraich, Diego — Rutgers Biomedical and Health Sciences
  • Study coordinator: Fraidenraich, Diego

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.